{"id":"fexofenadine-hcl","safety":{"commonSideEffects":[{"rate":"6-8","effect":"Headache"},{"rate":"2-3","effect":"Nausea"},{"rate":"1-2","effect":"Dyspepsia"},{"rate":"1-2","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL1200618","moleculeType":"Small molecule","molecularWeight":"538.13"},"_dailymed":{"setId":"25e72bd3-25c6-4943-92bb-27f9543e2d8a","title":"ALLERGY RELIEF (FEXOFENADINE HCL) CAPSULE, COATED [ALLEGIANT HEALTH]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fexofenadine competitively binds to peripheral H1 histamine receptors on mast cells and basophils, preventing histamine-induced allergic symptoms such as itching, hives, and rhinitis. Unlike first-generation antihistamines, it is highly selective for peripheral H1 receptors and does not significantly penetrate the central nervous system, resulting in minimal sedation.","oneSentence":"Fexofenadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without crossing the blood-brain barrier.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:21:57.414Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic rhinitis (seasonal and perennial)"},{"name":"Chronic idiopathic urticaria"}]},"trialDetails":[{"nctId":"NCT07487909","phase":"PHASE1, PHASE2","title":"A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","startDate":"2025-09-30","conditions":"Healthy","enrollment":47},{"nctId":"NCT05263206","phase":"PHASE3","title":"Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)","status":"RECRUITING","sponsor":"Sanofi","startDate":"2022-02-15","conditions":"Pruritus","enrollment":284},{"nctId":"NCT02592317","phase":"PHASE1","title":"A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2016-02-12","conditions":"Prostatic Neoplasms, Castration-Resistant","enrollment":23},{"nctId":"NCT07118215","phase":"PHASE1","title":"A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin","status":"RECRUITING","sponsor":"Karuna Therapeutics, Inc., a Bristol Myers Squibb company","startDate":"2025-09-29","conditions":"Healthy Volunteers","enrollment":60},{"nctId":"NCT05720455","phase":"PHASE4","title":"Study to Assess Safety and Efficacy of Fexofenadine Hydrochloride (HCL) + Pseudoephedrine HCL Fixed Dose Combination in Indian Male and Female Participants With Allergic Rhinitis (AR) Who Are 12 Years and Above","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-06-15","conditions":"Rhinitis Allergic","enrollment":203},{"nctId":"NCT07381803","phase":"PHASE3","title":"The Impact of Fexofenadine Hydrochloride on the Prognosis of Patients Post-Acute Myocardial Infarction","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-27","conditions":"Zhejiang University","enrollment":2804},{"nctId":"NCT06785298","phase":"PHASE2, PHASE3","title":"Fexofenadine as Adjuvant Therapy in Parkinson Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-10","conditions":"Parkinson Disease","enrollment":46},{"nctId":"NCT04534153","phase":"EARLY_PHASE1","title":"Excipient Effect on Drug Absorption in Humans","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2023-01-31","conditions":"The Impact of Excipients on Drug Absorption","enrollment":12},{"nctId":"NCT04568902","phase":"PHASE1","title":"Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2020-09-30","conditions":"Breast Neoplasms","enrollment":33},{"nctId":"NCT06019728","phase":"PHASE4","title":"A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-11-10","conditions":"Fabry's Disease","enrollment":8},{"nctId":"NCT02966665","phase":"PHASE1","title":": Vascular Function in Health and Disease","status":"RECRUITING","sponsor":"Russell Richardson","startDate":"2008-09","conditions":"Chronic Obstructive Pulmonary Disease, Pulmonary Artery Hypertension, Heart Failure","enrollment":420},{"nctId":"NCT05118672","phase":"PHASE3","title":"Phase 3 Clinical Trial to Evaluate Paracetamol /Fexofenadine /Phenylephrine in Flu and Cold Treatment","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2025-03-26","conditions":"Cold, Flu Symptom","enrollment":567},{"nctId":"NCT06284902","phase":"PHASE1","title":"Bioavailability Study of Fexofenadine HCl New Formulation Tablet","status":"COMPLETED","sponsor":"Opella Healthcare Group SAS, a Sanofi Company","startDate":"2024-02-23","conditions":"Healthy Volunteers","enrollment":25},{"nctId":"NCT05692154","phase":"PHASE3","title":"A Placebo-controlled Study of 2-day Pre-treatment With Fexofenadine in Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Opella Healthcare Group SAS, a Sanofi Company","startDate":"2023-01-23","conditions":"Seasonal Allergic Rhinitis","enrollment":95},{"nctId":"NCT05264025","phase":"PHASE1, PHASE2","title":"Fexofenadine in Patients With Active Rheumatoid Arthritis","status":"RECRUITING","sponsor":"October 6 University","startDate":"2022-06-01","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT04688788","phase":"PHASE3","title":"Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-04-28","conditions":"Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis","enrollment":600},{"nctId":"NCT04726345","phase":"PHASE2","title":"Effect of Antihistamines on Ureteral Stent-Related Symptoms","status":"COMPLETED","sponsor":"Columbia University","startDate":"2021-06-29","conditions":"Nephrolithiasis","enrollment":78},{"nctId":"NCT06779253","phase":"PHASE1","title":"A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects","status":"COMPLETED","sponsor":"Abbisko Therapeutics Co, Ltd","startDate":"2025-03-14","conditions":"Healthy Subjects","enrollment":39},{"nctId":"NCT06466421","phase":"PHASE4","title":"Fexofenadine Versus Gabapentin for Uremic Pruritus in Patients on Regular Hemodialysis","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-07-01","conditions":"Uremic Pruritus, Chronic Kidney Disease-associated Pruritus, Hemodialysis","enrollment":60},{"nctId":"NCT06205381","phase":"PHASE1","title":"Assessment of the Safety, Tolerability and Pharmacokinetics of AV078 in Healthy Volunteers","status":"COMPLETED","sponsor":"Aeovian Pharmaceuticals, Inc.","startDate":"2024-01-31","conditions":"Healthy Participants","enrollment":89},{"nctId":"NCT06629337","phase":"NA","title":"Effect of Aerobic Exercise with Blood Flow Restriction on Post-exercise Hypotension in Young Adults: the Role of Histamine Receptors","status":"COMPLETED","sponsor":"California Baptist University","startDate":"2024-04-01","conditions":"Prehypertension (elevated Blood Pressure) or Hypertension","enrollment":10},{"nctId":"NCT00783211","phase":"PHASE4","title":"Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-08-01","conditions":"Seasonal Allergic Rhinitis","enrollment":722},{"nctId":"NCT00783133","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03177)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-11-01","conditions":"Seasonal Allergic Rhinitis","enrollment":131},{"nctId":"NCT00783146","phase":"PHASE4","title":"Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR) (Study P04054)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2004-08-01","conditions":"Seasonal Allergic Rhinitis","enrollment":728},{"nctId":"NCT06548204","phase":"PHASE2","title":"Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2024-09","conditions":"ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":165},{"nctId":"NCT03635957","phase":"PHASE4","title":"Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2018-09-26","conditions":"Gout","enrollment":14},{"nctId":"NCT03994731","phase":"PHASE4","title":"Study of KRYSTEXXA® (Pegloticase) Plus Methotrexate in Participants With Uncontrolled Gout","status":"COMPLETED","sponsor":"Amgen","startDate":"2019-06-13","conditions":"Gout","enrollment":152},{"nctId":"NCT04450134","phase":"NA","title":"Histamine H1/H2 Receptors and Training Adaptations","status":"COMPLETED","sponsor":"University Ghent","startDate":"2019-10-02","conditions":"Exercise Training, Physical Activity","enrollment":19},{"nctId":"NCT03933007","phase":"PHASE4","title":"Relation Between Blood Concentration of Colchicine and Response to Colchicine Treatment in Gout Flare","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-09-10","conditions":"Gout Flare","enrollment":26},{"nctId":"NCT00647985","phase":"PHASE1","title":"Food Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-11","conditions":"Healthy","enrollment":28},{"nctId":"NCT00649376","phase":"PHASE1","title":"Fasting Study of Fexofenadine Tablets 180 mg and Allegra® Tablets 180 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2003-10","conditions":"Healthy","enrollment":68},{"nctId":"NCT05131555","phase":"NA","title":"Influence of Endurance Exercise and Histamine Receptors on the Gene Expression in Skeletal Muscle","status":"COMPLETED","sponsor":"University Ghent","startDate":"2021-08-16","conditions":"Exercise, Histamine","enrollment":14},{"nctId":"NCT03720366","phase":"PHASE1","title":"A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients","status":"COMPLETED","sponsor":"Celgene","startDate":"2018-10-04","conditions":"Leukemia, Myeloid, Acute","enrollment":40},{"nctId":"NCT06152497","phase":"NA","title":"The Role of Histamine in Muscle Protein Synthesis Following Resistance Training","status":"RECRUITING","sponsor":"University Ghent","startDate":"2023-09-01","conditions":"Histamine","enrollment":50},{"nctId":"NCT05820243","phase":"NA","title":"Determinants of Changes in Arterial Load Following Exercise","status":"UNKNOWN","sponsor":"University of Delaware","startDate":"2023-05-12","conditions":"Post-Exercise Hypotension","enrollment":25},{"nctId":"NCT05932277","phase":"PHASE1","title":"A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-06-29","conditions":"Healthy Volunteers","enrollment":22},{"nctId":"NCT05461456","phase":"PHASE1","title":"Bioavailability and Tolerability of Fexofenadine Hydrochloride Topical Lotion 1%","status":"COMPLETED","sponsor":"OrchestratePharma GmbH","startDate":"2022-04-01","conditions":"Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Rash","enrollment":12},{"nctId":"NCT02908750","phase":"PHASE1","title":"Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-03-02","conditions":"Non Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT04814498","phase":"PHASE1","title":"Drug-Drug Interaction (DDI) Study in Healthy Volunteers","status":"COMPLETED","sponsor":"Blade Therapeutics","startDate":"2021-05-03","conditions":"Drug Drug Interaction","enrollment":16},{"nctId":"NCT04224428","phase":"PHASE3","title":"Role of Fexofenadine in Diabetic Kidney Disease","status":"COMPLETED","sponsor":"Tanta University","startDate":"2020-01-01","conditions":"Diabetic Kidney Disease","enrollment":60},{"nctId":"NCT03664882","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Fexofenadine in Subjects Suffering From Seasonal Allergic Rhinitis in Presence of Pollutants","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-09-17","conditions":"Rhinitis Seasonal","enrollment":240},{"nctId":"NCT00794768","phase":"PHASE4","title":"Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-11","conditions":"Seasonal Allergic Rhinitis","enrollment":118},{"nctId":"NCT00794248","phase":"PHASE4","title":"Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-11","conditions":"Seasonal Allergic Rhinitis","enrollment":122},{"nctId":"NCT05150899","phase":"","title":"Role of Antihistaminic in Acute Renal Colic Prevent Pain Recurrence and Expulsion of Ureteric Stone ≤ 1cm","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2021-11-30","conditions":"Renal Colic, Ureter Stone","enrollment":100},{"nctId":"NCT02360644","phase":"NA","title":"Drug Metabolizing Enzyme and Transporter Function in Chronic Kidney Disease","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2014-10","conditions":"Chronic Kidney Diseases, Deficiency, Vitamin D","enrollment":23},{"nctId":"NCT03108274","phase":"PHASE1","title":"A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy Participants","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2017-04-18","conditions":"Healthy","enrollment":35},{"nctId":"NCT03425097","phase":"PHASE2","title":"Fexofenadine Use in Gastroesophageal Reflux Symptoms","status":"TERMINATED","sponsor":"Stanford University","startDate":"2018-02-07","conditions":"Gastroesophageal Reflux","enrollment":11},{"nctId":"NCT04527562","phase":"NA","title":"Colchicine in Moderate Symptomatic COVID-19 Patients","status":"COMPLETED","sponsor":"Dhaka Medical College","startDate":"2020-07-14","conditions":"Covid19","enrollment":299},{"nctId":"NCT01586091","phase":"PHASE4","title":"Safety Study of Levocetirizine and Fexofenadine","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2011-02","conditions":"Pruritus, Chronic Urticaria, Allergic Rhinitis","enrollment":18},{"nctId":"NCT02590185","phase":"NA","title":"MetAbolism vaRiability of VEnLafaxine","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Major Depressive Disorders","enrollment":205},{"nctId":"NCT01298505","phase":"PHASE1","title":"A Study To Investigate The Safety And Toleration Of Multiple Oral Doses Of PF-03654764 In Combination With Fexofenadine In Healthy Subjects","status":"TERMINATED","sponsor":"Pfizer","startDate":"2010-06-04","conditions":"Healthy","enrollment":36},{"nctId":"NCT00435461","phase":"PHASE4","title":"Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-12-20","conditions":"Rhinitis, Allergic, Seasonal","enrollment":1000},{"nctId":"NCT03078777","phase":"PHASE4","title":"The Effect Dialysis on the Pharmacokinetics of Fexofenadine","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2017-11-29","conditions":"Hemodialysis","enrollment":30},{"nctId":"NCT00866788","phase":"PHASE2","title":"A Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihistamine Treatment (H1)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2009-03","conditions":"Chronic Idiopathic Urticaria","enrollment":90},{"nctId":"NCT03183297","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001","status":"UNKNOWN","sponsor":"Sen-Jam Pharmaceutical","startDate":"2017-08","conditions":"Veisalgia","enrollment":48},{"nctId":"NCT01526213","phase":"NA","title":"Do Furanocoumarins Mediate the Fexofenadine-grapefruit Juice Interaction?","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2009-09","conditions":"Food-drug Interaction","enrollment":18},{"nctId":"NCT02391688","phase":"PHASE1","title":"Evaluation of the Potential Pharmacokinetic Interactions Between Probe Drugs in the Geneva Phenotyping Cocktail","status":"COMPLETED","sponsor":"Jules Desmeules","startDate":"2014-11","conditions":"Drug Interaction","enrollment":30},{"nctId":"NCT03012763","phase":"PHASE1","title":"Oral Pharmacokinetics of Sulfasalazine, Paracetamol, Fexofenadine and Valsartan Using Different Administration Mediums","status":"COMPLETED","sponsor":"University Medicine Greifswald","startDate":"2016-04","conditions":"Pharmacokinetics, Magnetic Resonance Imaging, Administration, Oral","enrollment":9},{"nctId":"NCT00502775","phase":"PHASE4","title":"Fluticasone Furoate Nasal Spray Versus Oral Fexofenadine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08","conditions":"Rhinitis, Allergic, Seasonal","enrollment":680},{"nctId":"NCT02175485","phase":"PHASE4","title":"Evaluation of Efficacy of Dellegra in Exposure Unit","status":"COMPLETED","sponsor":"Sanofi","startDate":"2014-06","conditions":"Rhinitis Allergic","enrollment":24},{"nctId":"NCT02551536","phase":"PHASE4","title":"Montelukast and Fexofenadine Versus Montelukast and Levocetrizine Combination in Allergic Rhinitis","status":"COMPLETED","sponsor":"Indira Gandhi Medical College, Shimla","startDate":"2014-04","conditions":"Allergic Rhinitis","enrollment":70},{"nctId":"NCT02438072","phase":"NA","title":"Drug Metabolism and Antidepressant","status":"UNKNOWN","sponsor":"University Hospital, Geneva","startDate":"2014-12","conditions":"Depression","enrollment":100},{"nctId":"NCT01469234","phase":"PHASE4","title":"A Study of Onset of Action of Loratadine and Fexofenadine in Participants With Seasonal Allergic Rhinitis (P08712)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10","conditions":"Rhinitis","enrollment":255},{"nctId":"NCT01172522","phase":"PHASE2","title":"Topical Treatment of Under Eye Dark Circles and Swelling","status":"COMPLETED","sponsor":"The Connecticut Sinus Center, PC","startDate":"2010-09","conditions":"Edema","enrollment":30},{"nctId":"NCT01731067","phase":"PHASE1","title":"Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot","status":"COMPLETED","sponsor":"Jules Desmeules","startDate":"2012-11","conditions":"Healthy Volunteers","enrollment":10},{"nctId":"NCT02157558","phase":"PHASE1","title":"An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-07","conditions":"Drug Interactions","enrollment":24},{"nctId":"NCT02171546","phase":"PHASE1","title":"Relative Bioavailability of Dabigatran Etexilate Capsules With and Without Quinidine Sulfate Tablets and to Measure the Effect of Quinidine on the Absorption of Fexofenadine in Healthy Male and Female Volunteers","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2007-11","conditions":"Healthy","enrollment":42},{"nctId":"NCT00562120","phase":"PHASE2","title":"A Study to Test a New Decongestant in Patients With Allergic Rhinitis Following a Nasal Allergen Challenge","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-12","conditions":"Allergic Rhinitis","enrollment":21},{"nctId":"NCT01852318","phase":"PHASE4","title":"Pregabalin for the Treatment of Uremic Pruritus","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2014-04","conditions":"Uremic Pruritus","enrollment":210},{"nctId":"NCT01940393","phase":"PHASE4","title":"Evaluation of the Inhibitory Effect of 5 Anti-Histamines in Urticaria","status":"COMPLETED","sponsor":"Grupo de Alergología Clínica y Experimental","startDate":"2013-08","conditions":"Urticaria","enrollment":150},{"nctId":"NCT02056743","phase":"PHASE1","title":"Clinical Trials on Evaluate the Red Ginseng and Fermented-Red Ginseng Affect to Drug Metabolizing Enzyme and Transporter in Healthy Volunteers","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","startDate":"2013-09","conditions":"Healthy","enrollment":30},{"nctId":"NCT00542607","phase":"PHASE4","title":"Efficacy and Safety of Levocetirizine and Fexofenadine in Reducing Symptoms of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2002-09","conditions":"Rhinitis, Allergic, Seasonal","enrollment":94},{"nctId":"NCT01244230","phase":"PHASE2, PHASE3","title":"Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Atopic Dermatitis","enrollment":100},{"nctId":"NCT01244217","phase":"PHASE2, PHASE3","title":"Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Perennial Allergic Rhinitis (PAR)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-10","conditions":"Rhinitis Perennial","enrollment":100},{"nctId":"NCT01306721","phase":"PHASE3","title":"Fexofenadine HCL - Pseudoephedrine HCL Combination Versus Allegra in Patients With Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2011-02","conditions":"Rhinitis Seasonal","enrollment":520},{"nctId":"NCT01856348","phase":"PHASE1","title":"Vitamin D3, Folic Acid and Fexofenadine in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2013-05","conditions":"Physiological Effects of Vitamin D","enrollment":10},{"nctId":"NCT01888718","phase":"PHASE1","title":"Bioequivalence Study of Fexofenadine Hydrochloride Orally Disintegrated Tablets 30 mg Under Fasting Condition","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2011-02","conditions":"Healthy","enrollment":80},{"nctId":"NCT01767272","phase":"NA","title":"Dose Proportionality of Fexofenadine in Healthy Human Egyptian Volunteers","status":"COMPLETED","sponsor":"Damanhour University","startDate":"2012-12","conditions":"Healthy","enrollment":25},{"nctId":"NCT01683552","phase":"PHASE2","title":"Aprepitant in the Management of Biological Therapies-related Severe Pruritus","status":"COMPLETED","sponsor":"Campus Bio-Medico University","startDate":"2010-09","conditions":"ITCH","enrollment":45},{"nctId":"NCT00420082","phase":"PHASE2","title":"A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of Bilastine in the Vienna Challenge Chamber","status":"COMPLETED","sponsor":"Faes Farma, S.A.","startDate":"2006-10","conditions":"Seasonal Allergic Rhinitis","enrollment":75},{"nctId":"NCT00637611","phase":"PHASE4","title":"Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-02","conditions":"Seasonal Allergic Rhinitis","enrollment":1010},{"nctId":"NCT00636870","phase":"PHASE4","title":"Fexofenadine (Allegra®) in Healthy Adults Who Have Been Identified as Slow Metabolizers for Desloratadine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-02","conditions":"Allergic Rhinitis","enrollment":220},{"nctId":"NCT00638118","phase":"PHASE4","title":"Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-02","conditions":"Allergic Rhinitis","enrollment":48},{"nctId":"NCT00547768","phase":"PHASE4","title":"Comparative Study Evaluating the Effects of Fexofenadine HCI 180 mg With Orange Juice Versus Placebo With Orange Juice in a Skin Wheal and Flare Challenge Model.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-11","conditions":"Allergy","enrollment":36},{"nctId":"NCT00637455","phase":"PHASE4","title":"Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-09","conditions":"Seasonal Allergic Rhinitis","enrollment":72},{"nctId":"NCT00637884","phase":"PHASE4","title":"A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Study Designed to Evaluate the Efficacy of Fexofenadine HCl 180 mg for Preventing and Controlling Cat Allergy Symptoms","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-11","conditions":"Cat Induced Allergic Rhinitis","enrollment":70},{"nctId":"NCT00637585","phase":"PHASE4","title":"Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-12","conditions":"Allergic Rhinitis","enrollment":42},{"nctId":"NCT01033396","phase":"PHASE2","title":"The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-01","conditions":"Allergic Rhinitis","enrollment":64},{"nctId":"NCT01133483","phase":"PHASE1","title":"Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr.Reddy's Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2007-04","conditions":"Healthy","enrollment":38},{"nctId":"NCT01133470","phase":"PHASE1","title":"Bioequivalence Study of Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's and Allegra D 24 Hour ER Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2007-02","conditions":"Healthy","enrollment":54},{"nctId":"NCT01066754","phase":"PHASE1","title":"Bioequivalence Study of Dr.Reddy's Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2002-04","conditions":"Healthy","enrollment":44},{"nctId":"NCT01066767","phase":"PHASE1","title":"Bioequivalence Study of Dr. Reddy's Laboratories Limited Fexofenadine Hydrochloride 180 mg Tablets Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","startDate":"2002-04","conditions":"Healthy","enrollment":30},{"nctId":"NCT00741897","phase":"PHASE4","title":"Fexofenadine Study On Filipino Children for The Relief of Perennial And Intermittent Allergic Rhinitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-03","conditions":"Rhinitis, Allergic, Perennial","enrollment":264},{"nctId":"NCT00835276","phase":"PHASE1","title":"Fexofenadine Hydrochloride 180 mg Tablets Under Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-03","conditions":"Healthy","enrollment":60},{"nctId":"NCT00835640","phase":"PHASE1","title":"Fexofenadine Hydrochloride 180 mg Tablets Under Non-Fasting Conditions","status":"COMPLETED","sponsor":"Teva Pharmaceuticals USA","startDate":"2002-01","conditions":"Healthy","enrollment":24},{"nctId":"NCT00045955","phase":"PHASE3","title":"Long-Term Safety Performance of Fexofenadine in Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-02","conditions":"Asthma","enrollment":1200},{"nctId":"NCT00044811","phase":"PHASE3","title":"Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-03","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00044824","phase":"PHASE3","title":"Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2002-02","conditions":"Asthma","enrollment":1000},{"nctId":"NCT00261079","phase":"PHASE4","title":"Fexofenadine in Pruritic Skin Disease","status":"COMPLETED","sponsor":"Handok Inc.","startDate":"2005-04","conditions":"Pruritus","enrollment":435}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[{"date":"20160126","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA079043"},{"date":"20110622","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA079043"},{"date":"20100528","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA079043"},{"date":"20220517","type":"SUPPL","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA079043"},{"date":"20100317","type":"ORIG","sponsor":"DR REDDYS LABS LTD","applicationNumber":"ANDA079043"},{"date":"20141118","type":"ORIG","sponsor":"DR REDDYS","applicationNumber":"ANDA076667"},{"date":"20160126","type":"SUPPL","sponsor":"DR REDDYS","applicationNumber":"ANDA076667"},{"date":"20191018","type":"ORIG","sponsor":"GRANULES","applicationNumber":"ANDA211075"},{"date":"20240104","type":"SUPPL","sponsor":"GRANULES","applicationNumber":"ANDA211075"},{"date":"20160819","type":"ORIG","sponsor":"HETERO LABS LTD V","applicationNumber":"ANDA204097"},{"date":"20260318","type":"SUPPL","sponsor":"UNIQUE","applicationNumber":"ANDA210137"},{"date":"20180813","type":"ORIG","sponsor":"UNIQUE","applicationNumber":"ANDA210137"}],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Allegra"],"phase":"marketed","status":"active","brandName":"fexofenadine HCl","genericName":"fexofenadine HCl","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fexofenadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without crossing the blood-brain barrier. Used for Allergic rhinitis (seasonal and perennial), Chronic idiopathic urticaria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}